As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

GLP-1 receptor agonists, originally developed for managing type ... gained widespread attention for its significant weight ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death ... based Mayo Clinic researchers analyzed the effect GLP-1s and SGLT2s medications had on stroke survivors' risk of ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience is advancing its DehydraTECH drug delivery platform to compete in the ...

The GLP-1 medications liraglutide and semaglutide ... medication use with recurrent stroke and no additional variables. “The potential protective effects of the medications were hidden because those ...